Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

Fecha de publicación: 15/10/2008

Autores de IIS La Fe

Miguel Ángel Sanz Alonso

Autor
Pau Montesinos Fernández

Autor
Cristina Rivas Juesas

Autor
Maria José Calasanz Abinzano

Autor
Eva Barragán González

Autor
Pascual Bolufer Gilabert

Autor

Participantes ajenos a IIS La Fe

Vellenga E
Rayón C
de la Serna J
Parody R
Bergua JM
León A
Negri S
González M
Esteve J
Milone G
González JD
Amutio E
Brunet S
García-Laraña J
Colomer D
Chillón C
Lowenberg B

Grupos

Hematología y Hemoterapia

Investigador Principal

Javier De La Rubia Comos
Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina

Abstract

A previous report of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) Group showed that a risk-adapted strategy combining all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for induction and consolidation in newly diagnosed acute promyelocytic leukemia results in an improved outcome. Here we analyze treatment outcome of an enlarged series of patients who have been followed up for a median of 65 months. From November 1999 through July 2005 (LPA99 trial), 560 patients received induction therapy with ATRA plus idarubicin. Patients achieving complete remission received 3 courses of consolidation followed by maintenance with ATRA and low-dose chemotherapy. The 5-year cumulative incidence of relapse and disease-free survival were 11% and 84%, respectively. These results compare favorably with those obtained in the previous LPA96 study (P = .019 and P = .04, respectively). This updated analysis confirms the high antileukemic efficacy, low toxicity, and high degree of compliance of a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for consolidation therapy.